Jonathan Kimmelman /newsroom/taxonomy/term/1959/all en Experts: FDA approves much-debated Alzheimer's drug panned by experts /newsroom/channels/news/experts-fda-approves-much-debated-alzheimers-drug-panned-experts-331414 <p>U.S. government health officials approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease. The Food and Drug Administration (FDA) said it granted approval to the drug from Biogen based on results that seemed “reasonably likely” to benefit Alzheimer's patients. (<a href="https://www.ctvnews.ca/health/fda-approves-much-debated-alzheimer-s-drug-panned-by-experts-1.5459470" target="_blank">CTV News</a>)</p> Tue, 08 Jun 2021 20:48:35 +0000 frederique.mazerolle@mcgill.ca 269362 at /newsroom Expert opinion: COVID-19 vaccine rollout unlikely before fall 2021 /newsroom/channels/news/expert-opinion-covid-19-vaccine-rollout-unlikely-fall-2021-325084 <p>Experts working in the field of vaccine development tend to believe that an effective vaccine is not likely to be available for the general public before the fall of 2021. In a paper published recently in the <a href="https://link.springer.com/article/10.1007/s11606-020-06244-9"><i>Journal of General Internal Medicine</i></a>, a 91-led team published the results of a recent survey of 28 experts working in vaccinology.</p> Thu, 01 Oct 2020 15:30:00 +0000 katherine.gombay@mcgill.ca 241817 at /newsroom CTV NEWS | Hundreds of Canadians willing to be infected with coronavirus to speed vaccine research /newsroom/channels/news/ctv-news-hundreds-canadians-willing-be-infected-coronavirus-speed-vaccine-research-322221 <p>Thousands of healthy volunteers, including hundreds of Canadians, have offered to try getting injected with a potential vaccine and then purposely becoming infected with COVID-19 to test if the vaccine works. <strong>Jonathan Kimmelman</strong>, a professor of biomedical ethics at 91, expressed concerns about the risks.</p> Tue, 19 May 2020 17:28:29 +0000 amelia.souffrant@mail.mcgill.ca 211699 at /newsroom NATIONAL POST | Mom fears losing access to experimental drug that helped daughter after study ends /newsroom/channels/news/national-post-mom-fears-losing-access-experimental-drug-helped-daughter-after-study-ends-286237 <p>Jonathan Kimmelman, director of biomedical ethics at 91, agreed companies have some obligation to continue to provide care for patients who take part in studies to test experimental products. “Any time a patient participates in a trial, they’re volunteering their body to advance science,” he said from Montreal. “And if it’s a trial being run by a pharmaceutical company, they’re volunteering their bodies to advance the goals of the pharmaceutical company, whether that’s a big pharmaceutical company or a small one.</p> Tue, 27 Mar 2018 17:29:38 +0000 nathan.menezes@mail.mcgill.ca 35538 at /newsroom BLOOMBERG | Scientists Don't Fear a New Crispr Snag /newsroom/channels/news/bloomberg-scientists-dont-fear-new-crispr-snag-284111 <p>I talked this over with 91 medical ethicist Jonathan Kimmelman, who specializes in the risks of medical experiments and has written a book about them centered on the Jesse Gelsinger case. Of course, he says, money isn’t the only thing that might prevent medical researchers from being perfectly objective -- there’s the desire to be heroes, to beat rivals, and to help patients. A bigger concern is the fact that whatever is driving scientists, they can have blind spots just like everyone else.</p> Wed, 24 Jan 2018 00:25:01 +0000 laurie.devine@mcgill.ca 32890 at /newsroom Proliferating drug trials pose pitfalls for doctors and patients /newsroom/channels/news/proliferating-drug-trials-pose-pitfalls-doctors-and-patients-269946 <p> Thu, 31 Aug 2017 15:00:52 +0000 cynthia.lee@mcgill.ca 32226 at /newsroom Cancer researchers overestimate reproducibility of preclinical studies /newsroom/channels/news/cancer-researchers-overestimate-reproducibility-preclinical-studies-268784 <p>Cancer scientists overestimate the extent to which high-profile preclinical studies can be successfully replicated, new research from 91 suggests.</p> Wed, 28 Jun 2017 20:40:17 +0000 justin.dupuis@mcgill.ca 32027 at /newsroom Jonathan Kimmelman /newsroom/jonathan-kimmelman Tue, 26 Feb 2019 16:59:44 +0000 priya.pajel@mail.mcgill.ca 24543 at /newsroom Cancer research plagued by poor study design /newsroom/channels/news/cancer-research-plagued-poor-study-design-256090 <p>Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to a new study from 91 in Canada.</p> <p> Wed, 14 Oct 2015 18:41:04 +0000 melody.enguix@mcgill.ca 24536 at /newsroom